Telomir Pharmaceuticals (NASDAQ: TELO) has announced the peer-reviewed publication of preclinical data demonstrating that its lead candidate, Telomir-Zn, effectively suppresses tumor growth in prostate and triple-negative breast cancer (TNBC) models. The findings, published in the Journal of Oncology Research and Therapy, provide the scientific foundation for advancing Telomir-Zn into a Phase 1/2 clinical trial for TNBC, a particularly aggressive and difficult-to-treat form of breast cancer.
The study reveals that Telomir-Zn works by selectively modulating intracellular iron and copper levels, leading to the inhibition of histone demethylases—enzymes that play a role in gene expression. By depleting intracellular iron, Telomir-Zn selectively kills iron-dependent TNBC cells while sparing normal cells, even at concentrations more than 50-fold higher than those required to affect cancer cells. In prostate cancer models, the compound reactivated tumor-suppressor genes, further underscoring its potential as an epigenetic modulator.
In TNBC xenograft models, Telomir-Zn reduced primary tumor size across several cell lines and significantly reduced metastatic dissemination in HCC1806 xenografts. Notably, in BT-549 xenografts, combining Telomir-Zn with paclitaxel—a standard chemotherapy agent—produced significantly greater tumor reduction than either treatment alone. However, MDA-MB-231 xenografts did not respond, indicating tumor-specific differences in sensitivity that will be important for patient selection in future clinical trials.
The announcement is significant for the biotechnology industry and for patients with TNBC, a subtype that accounts for approximately 15% of breast cancer cases and is associated with a poorer prognosis due to limited targeted treatment options. Current therapies often rely on chemotherapy, and there is a high unmet need for novel approaches. Telomir-Zn's unique mechanism of action—targeting metal homeostasis and epigenetic pathways—offers a promising new avenue for treatment.
Telomir Pharmaceuticals is a clinical-stage biotechnology company focused on developing small-molecule therapeutics that target epigenetic and metabolic pathways implicated in cancer. The company has already received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial in patients with advanced or metastatic TNBC. The peer-reviewed data bolster the scientific rationale for this trial and may accelerate its initiation.
The potential impact of these findings extends beyond TNBC. The dual activity of Telomir-Zn in prostate and breast cancer models suggests it could have broad applicability across multiple cancer types that rely on similar metabolic dependencies. For business leaders and investors, this development highlights the growing interest in epigenetic therapies and metal homeostasis as targets for oncology.
The full press release is available at https://ibn.fm/mv3hn. More information about Telomir Pharmaceuticals can be found in their newsroom at https://ibn.fm/TELO.
